Remove clinical
article thumbnail

STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro

STAT

As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. The drug company accused four compound pharmacies of violating state laws because those versions were not approved by the U.S.

article thumbnail

Magic mushroom compound matches antidepressant in clinical trial

pharmaphorum

The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly. . The post Magic mushroom compound matches antidepressant in clinical trial appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders

STAT

Novo Nordisk filed lawsuits against two compounding pharmacies for selling adulterated and misbranded compounded drugs claiming to contain semaglutide, the active ingredient in Wegovy and Ozempic (see here and here ). Testing of compounded drugs from these pharmacies revealed unknown impurities up to 33%, the company claims.

article thumbnail

With new lawsuits, Novo Nordisk aims to crack down on compounded versions of Ozempic, Wegovy

Fierce Pharma

Three weeks after the FDA warned that some pharmacies are making unauthorized versio | Novo Nordisk filed five lawsuits in four states on Tuesday, charging health spas, clinics and pharmacies with false advertising, trademark infringement and unlawful sales of compounded versions of diabetes and weight loss drugs Ozempic and Wegovy.

article thumbnail

STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients

STAT

Food and Drug Administration and a trade group that represents large compound pharmacies have resolved a long-running dispute over the use of bulk ingredients, clearing the way for some compounded medicines to become available more quickly. Continue to STAT+ to read the full story…

article thumbnail

Interview: CRO Emmes on the unique challenges of clinical trials using psychedlics and the FDA guidance

Outsourcing Pharma

Feedback has been submitted to the US Food and Drug Administration (FDA) with guidelines intended for sponsors of clinical trials related to psychedelic compounds.

FDA 96
article thumbnail

Why IV Automation Is Critical for Sterile Compounding

Omnicell

Stephanie Gallagher, PharmD, MBA Senior Clinical Product Marketing Manager, Omnicell Imagine if Amazon lost one out of every 10 packages. So why, as clinicians, are we not focused on improving the documented one in 10 inaccuracies in sterile compounded products? Or the airlines lost 10% of passenger bags.